5 results
8-K
EX-99
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
11 Sep 06
Regulation FD Disclosure
12:00am
that the most recent transactions are a great leap forward, not
only for the Company but for each and every stakeholder in our organization.
Now I'm
S-4
EX-10.8
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Jul 98
Registration of securities issued in business combination transactions
12:00am
, a "Stakeholder
Agent"), and the Escrow Agent with an accounting certified by the Chief
Financial Officer of Parent of all Preclosing Company Revenues … a statement to each
of the Stakeholder Agents that describes any deposit, distribution or investment
activity with respect to the Escrowed Amount
S-4
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Jul 98
Registration of securities issued in business combination transactions
12:00am
subsequently
agreed to reduce its fees and accept the right to receive 3.39113385 percent of
the Stakeholder Closing Consideration (as defined in the Merger … Agreement) and
3.39113385 percent of the Stakeholder Milestone Consideration (as defined in the
Merger Agreement) as full and complete satisfaction
S-4
EX-2.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Jul 98
Registration of securities issued in business combination transactions
12:00am
pursuant to
Section 1.10 below. In addition, the Milestone Consideration allocable to the
recipients of the Stakeholder Closing Consideration … ) (the "Stakeholder Closing
Consideration") shall be delivered to Lehman.
(6) 1.69556693 percent of the Stakeholder
- Prev
- 1
- Next